CSM
GSK icon

CAMG Solamere Management’s GSK GSK Stock Holding History

CAMG Solamere Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21,000
Closed -$937K – 83
2021
Q1 		$937K Sell
21,000
-7,320
-26% -$332K 0.81% 49
2020
Q4 		$1.3M Sell
28,320
-14,103
-33% -$648K 1.09% 34
2020
Q3 		$2M Sell
42,423
-3,294
-7% -$165K 1.12% 27
2020
Q2 		$2.33M Sell
45,717
-45,885
-50% -$2.35M 1.28% 17
2020
Q1 		$4.34M Sell
91,602
-33,511
-27% -$1.79M 2.28% 6
2019
Q4 		$7.35M Buy
125,113
+5,580
+5% +$310K 3.39% 3
2019
Q3 		$6.37M Sell
119,533
-8,702
-7% -$448K 3.19% 3
2019
Q2 		$6.42M Buy
128,235
+4,729
+4% +$237K 2.94% 6
2019
Q1 		$6.45M Buy
123,506
+7,514
+6% +$375K 3.2% 2
2018
Q4 		$5.54M Buy
115,992
+8,891
+8% +$438K 3.09% 5
2018
Q3 		$5.38M Buy
107,101
+16,499
+18% +$838K 2.75% 5
2018
Q2 		$4.57M Buy
90,602
+3,794
+4% +$191K 2.25% 10
2018
Q1 		$4.24M Buy
+86,808
New +$4.04M 1.93% 10

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CAMG Solamere Management's GSK Position: Q2 2021 in Review

CAMG Solamere Management sold out of GSK (GSK) in Q2 2021, closing a stake of 21,000 shares — an estimated $937K sold.

CAMG Solamere Management first reported a position in GSK in Q1 2018 and held it in 13 quarters. The position peaked at $7.35M in Q4 2019. 799 funds tracked by Wall St. Rank hold GSK as of Q2 2021.

  • CAMG Solamere Management reported no remaining GSK position as of Q2 2021 after selling out during the quarter.
  • CAMG Solamere Management sold 21,000 GSK shares in Q2 2021, an estimated $937K.
  • CAMG Solamere Management first reported a position in GSK in Q1 2018 and held it in 13 quarters.
  • CAMG Solamere Management's GSK position peaked at $7.35M in Q4 2019.
  • 799 funds tracked by Wall St. Rank held GSK as of Q2 2021.

Based on CAMG Solamere Management's 13F filing for Q2 2021, filed 13 Aug 2021.